Published in J Mol Model on April 23, 2014
Evolving concepts of rheumatoid arthritis. Nature (2003) 14.31
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Points of control in inflammation. Nature (2002) 10.61
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des (2006) 2.53
Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci (2013) 1.47
Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci (2010) 1.41
Matrix metalloproteinase-8 facilitates neutrophil migration through the corneal stromal matrix by collagen degradation and production of the chemotactic peptide Pro-Gly-Pro. Am J Pathol (2008) 1.33
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J Comput Aided Mol Des (2008) 1.32
Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J Chem Inf Model (2007) 1.18
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer (2003) 1.01
Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8). J Med Chem (2009) 1.01
Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res (2010) 1.00
Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors. J Chem Theory Comput (2013) 0.99
Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today (2007) 0.98
Rheumatoid arthritis and salivary biomarkers of periodontal disease. J Clin Periodontol (2010) 0.98
Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr Med Chem (2008) 0.96
A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. J Med Chem (2004) 0.92
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem (2000) 0.88
Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM-GBSA calculation. J Comput Chem (2011) 0.87
In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet (2004) 0.86
Insight into the degradation of type-I collagen fibrils by MMP-8. J Mol Biol (2013) 0.85
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem (2000) 0.85
Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8. Bioorg Med Chem (2005) 0.85
Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett (2005) 0.84
Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis. J Mol Graph Model (2013) 0.84
Structure and evolutionary aspects of matrix metalloproteinases: a brief overview. Mol Cell Biochem (2003) 0.83
Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Res Ther (2010) 0.83
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem (2011) 0.82
Inhibitory effect of quercetin on matrix metalloproteinase 9 activity molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction. Eur J Pharmacol (2010) 0.82
Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. J Med Chem (2001) 0.82
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J Med Chem (2011) 0.81
Immunopathology of rheumatoid arthritis. Curr Top Med Chem (2013) 0.80
Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. Bioorg Med Chem (2002) 0.78
Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem (2008) 0.78
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification. Bioorg Med Chem Lett (2007) 0.78
[Bone and cartilage destruction in rheumatoid arthritis]. Clin Calcium (2012) 0.77
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors. Eur J Med Chem (2007) 0.77
Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett (2001) 0.75
Lead identification and optimization of novel collagenase inhibitors; pharmacophore and structure based studies. Bioinformation (2012) 0.75
Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors. J Mol Graph Model (2013) 0.75
Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors. J Comput Aided Mol Des (2012) 0.75
The cost of coverage: rural health insurance in China. Health Policy Plan (1996) 1.21
Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis. J Mol Graph Model (2013) 0.84
Characterization and in vitro evaluation of electrospun chitosan/polycaprolactone blend fibrous mat for skin tissue engineering. J Mater Sci Mater Med (2015) 0.79
Lead identification and optimization of novel collagenase inhibitors; pharmacophore and structure based studies. Bioinformation (2012) 0.75
Molecular docking and dynamics simulation study on the influence of Zn2+ on the binding modes of aggrecanase with its inhibitors. Comb Chem High Throughput Screen (2014) 0.75